Cochlear Limited provides implantable hearing solutions principally in the Americas, Europe, the Middle East, Africa and the Asia Pacific. The company offers cochlear implants, including Nucleus 7 and Kanso sound processors; Carina middle-ear implants and accessories and Baha bone conduction implants. Cochlear Limited is based in Sydney, Australia.
| Revenue (Most Recent Fiscal Year) | $1.53B |
| Net Income (Most Recent Fiscal Year) | $251.85M |
| PE Ratio (Current Year Earnings Estimate) | 38.77 |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 9.48 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 38.34 |
| Pre-Tax Margin (Trailing 12 Months) | 22.13% |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -- |
| Return on Assets (Trailing 12 Months) | -- |
| Current Ratio (Most Recent Fiscal Quarter) | 2.35 |
| Quick Ratio (Most Recent Fiscal Quarter) | 1.52 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | 1.28 |
| Book Value per Share (Most Recent Fiscal Quarter) | $9.66 |
| Earnings per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Year) | $1.94 |
| Diluted Earnings per Share (Trailing 12 Months) | -- |
| Exchange | -- |
| Sector | -- |
| Industry | -- |
| Common Shares Outstanding | 130.80M |
| Free Float | -- |
| Market Capitalization | $11.97B |
| Average Volume (Last 20 Days) | 6546.20 |
| Beta (Past 60 Months) | 0.91 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | -- |
| Percentage Held By Institutions (Latest 13F Reports) | 0.00% |
| Annual Dividend (Based on Last Quarter) | $1.25 |
| Dividend Yield (Based on Last Quarter) | 1.37% |